Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Rebecca Aft et al.|Clinical Cancer Research|2017Cited by 74
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their CombinationX. Cynthia, Lisa A. Carey, Vera J. Suman et al.|JAMA Oncology|2024Cited by 20
Shared and distinct molecular signatures of resistance to different endocrine therapies (Alliance A011106).Meenakshi Anurag, C X Ma, Yongchao Dou et al.|Journal of Clinical Oncology|2026Cited by 0